



A Festschrift Celebrating Dr. Dimiter Stanchev Dimitrov: Antibodies, Innovation, and Impact on Infectious Disease and Cancer Research

Guest Editors:

Dr. Ponraj Prabakaran

Prof. Dr. Tianlei Ying

Dr. Wei Li

Deadline for manuscript
submissions:

31 December 2024

Message from the Guest Editors

We are thrilled to announce a Special Issue dedicated to celebrating Dr. Dimiter Stanchev Dimitrov, the founding Editor-in-Chief of *Antibodies*. Dr. Dimitrov received his education at the University of Sofia, Bulgaria. His three decades at the NIH have been marked by pioneering work in antibody therapeutics, earning him recognition as a Senior Biomedical Researcher and an NCI Outstanding Mentor. Dr. Dimitrov also served as a Distinguished Professor of Medicine and Director of the Center for Antibody Therapeutics at the University of Pittsburgh.

He has made vital contributions to the development and use of human monoclonal antibodies. He is renowned for his work on display/screening/library methodologies and antibody engineering. His dedication to clinical research collaboration has paved the way for groundbreaking advancements in antibody-based medicine.

For this Special Issue, we eagerly await your contributions to this special edition of *Antibodies*, which promises to celebrate Dr. Dimitrov's remarkable achievements and inspire future generations of scientists to continue his legacy of pioneering antibody therapeutics and immunotherapies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Arne Skerra

Chair of Biological Chemistry,
Technical University of Munich,
Emil-Erlenmeyer-Forum 5, 85354
Freising (Weihenstephan),
Germany

Message from the Editor-in-Chief

Antibodies is a relatively new journal with a major focus on quick dissemination of knowledge related to antibodies, especially how to quickly translate basic research results to therapeutic applications. Because it covers all areas related to antibodies unexpected connections between different areas could be made, leading to major discoveries and opening new fields of research and development. This is enhanced by the large readership of the many antibody-related areas of research. A specific priority area is human monoclonal antibodies for therapy of diseases and aging.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, ESCI (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: CiteScore - Q2 (*Drug Discovery*)

Contact Us

Antibodies Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibodies
antibodies@mdpi.com
X@Antibodies_MDPI